Investigating the efficacy and safety of existing drugs in patients with rare immune diseases

This month the first study within the DRIMID consortium (DRIMID stands for Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases) has started.

CMS proposes coverage for pre-exposure prophylaxis regimens to prevent HIV

The Centers for Medicare and Medicaid Services on Wednesday proposed coverage for pre-exposure prophylaxis (PrEP) using antiretroviral therapy to prevent HIV infections. The news comes

July 14, 2023

ASCO 2024: the latest in cancer research

STAT will host a kickoff event May 31, featuring top experts in oncology, and will offer a live wrap-up broadcast on June 5. You can

May 28, 2024

Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C. – Biotech Investments

Issuer: Mainz BioMed N.V. / Key word(s): Conference 07.05.2024 / 14:01 CET/CEST The issuer is solely responsible for the content of this announcement. Mainz Biomed

May 8, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.